CLINICAL CASE OF SECONDARY ANTIPHOSPHOLIPID SYNDROME IN A NEPHROLOGICAL PATIENT
Keywords:
Antiphospholide syndrome, chronic glomerulonephritis, arterial hypertension.Abstract
The article describes a clinical case of late diagnosis of secondary aPL with multiinflammatory syndrome in a patient with chronic glomerulonephritis. The experience of Covid-19 led to the launch of systemic homeostasiological disorders, which manifested as thrombosis in the inferior vena cava, renal vein, and lower lobe pulmonary artery. In this case, the onset of the disease was “varicocele,” which most likely was a manifestation of thrombosis of the spermatic cord vein. The addition of arterial hypertension, anasarca, massive proteinuria with active urinary sediment, hypoproteinemia , hypercreatininemia was regarded as manifestations of clinical and laboratory signs of a mixed form of CGN with impaired renal function, which required pulse therapy with a glucocorticosteroid and a cytostatic in combination with combined nephroprotective therapy against the background of anticoagulants and antiplatelet agents .
References
Makarenko E.V., Antiphospholipid syndrome. Journal "Problems of Health and Ecology", 2017 P4-11.
Golovach I.Yu., Egudina E.D., Rekalov D.G. Kidney damage due to antiphospholipid syndrome. Review. Počki. 2019;8(3):161-173. dVol. 8, No. 3, 2019 http://kidneys.zaslavsky.com.ua.
Negrini S., Pappalardo F., Murdaca G. et al. The antiphospholipid syndrome: from pathophysiology to treatment // Clin Exp Med. - 2017. - No. 3. - R. 257–267.
Rai R., Swetha T. Association of anti-phospholipid antibodies with connective tissue diseases // Indian Dermatol Online J. - 2015. - No. 2. - R. 89–91.
Reshetnyak T.M., Vavilova T.V. Clinical and laboratory criteria for antiphospholipid syndrome - what a practitioner needs to know (lecture) // Clinical laboratory diagnostics. - 2010. - No. 11. - P. 13–20.
Arachchillage DRJ, Laffan M. Pathogenesis and management of antiphospholipid syndrome // Br J Haematol - 2017. - No. 2. - R. 181–195.
Antiphospholipid syndrome // Mayo Clinic. — 2022.
Gullapalli K., Prasad RM, Al- Abcha A Et al. Efficacy and Safety of Direct Oral Anticoagulants in Patients with Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis // Cureus. — 2022. — No. 9.
Capecchi M., Abbattista M., Ciavarella A. et al. Anticoagulant Therapy in Patients with Antiphospholipid Syndrome // J Clin Med. - 2022. - No. 23.
ФТ Хусанходжаева, ФЭ Салямова, НЗ Мухитдинова, Conferences, 2022. ЭФФЕКТИВНОСТЬ ВИТАМИНА Д У БОЛЬНЫХ С САХАРНЫМ ДИАБЕТОМ ПРИ ИНФЕКЦИИ МОЧЕВЫВОДЯЩИХ ПУТЕЙ. https://scholar.google.com/citations?view_op=view_citation&hl=ru&user=M4Ks_loAAAAJ&citation_for_view=M4Ks_loAAAAJ:Y0pCki6q_DkC
Допплеровское исследование почечных сосудов-лучший способ динамического контроля состояния трансплантированной почки Бобокулов Максуд Бегматович, Салямова Феруза Эркиновна. ФТ Хусанходжаева https://scholar.google.com/citations?view_op=view_citation&hl=ru&user=M4Ks_loAAAAJ&citation_for_view=M4Ks_loAAAAJ:Tyk-4Ss8FVUC
Хусанходжаева Ф. Т. и др. Оптимизация лечения инфекций мочевых путей у больных сахарным диабетом 2 типа путем добавления витамина Д //INTERDISCIPLINE INNOVATION AND SCIENTIFIC RESEARCH CONFERENCE. – 2022. – Т. 1. – №. 3. – С. 10-20.
Barnoyev Xabib Bobomurodovich, Shukurova Lobar Xusanovna, Xusanxodjaeva Feruza Tulkunovna SURUNKALI BUYRAK KASALLIGINING II-III BOSQICHIDA ANTIAGREGANT TERAPIYA FONIDA BUYRAK FUNKSIONAL ZAXIRASINI BAHOLASH // ORIENSS. 2021. №3. URL: https://cyberleninka.ru/article/n/surunkali-buyrak-kasalligining-ii-iii-bosqichida-antiagregant-terapiya-fonida-buyrak-funksional-zaxirasini-baholash
Daminova. K. M., & Xusanxodjaeva, F. T. (2022). СОВРЕМЕННЫЙ ПОДХОД К ВИТАМИНУ Д И СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКЕ. Медицина и инновации, 2(1). извлечено от https://inlibrary.uz/index.php/medicine_and_innovations/article/view/17410
Zhang J., Li C., Han X. et al. The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies // Ann Med. - 2021. - No. 1. - R. 1328–1339.
